Latest Insider Transactions at Harrow Health, Inc. (HROW)
This section provides a real-time view of insider transactions for Harrow Health, Inc. (HROW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of HARROW HEALTH, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of HARROW HEALTH, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
John P. Saharek CEO of ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
45,140
-13.09%
|
$1,850,740
$41.37 P/Share
|
|
Sep 11
2024
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+20.7%
|
$630,000
$7.37 P/Share
|
|
Apr 25
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.52%
|
$180,000
$9.97 P/Share
|
|
Apr 24
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,285
+0.22%
|
$82,850
$10.15 P/Share
|
|
Apr 23
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
11,715
+0.31%
|
$117,150
$10.29 P/Share
|
|
Apr 19
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
29,400
+0.77%
|
$294,000
$10.56 P/Share
|
|
Mar 28
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.32%
|
$600,000
$12.82 P/Share
|
|
Mar 22
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
9,000
+0.42%
|
$99,000
$11.59 P/Share
|
|
Mar 20
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,600
+1.35%
|
$455,400
$9.65 P/Share
|
|
Mar 01
2024
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.92%
|
$40,000
$8.75 P/Share
|
|
Feb 20
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Exercise of conversion of derivative security
|
Direct |
59,836
-2.73%
|
$598,360
$10.67 P/Share
|
|
Feb 20
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+6.41%
|
$1,500,000
$10.67 P/Share
|
|
Feb 20
2024
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Exercise of conversion of derivative security
|
Direct |
18,480
-3.15%
|
$184,800
$10.67 P/Share
|
|
Feb 20
2024
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+7.13%
|
$450,000
$10.67 P/Share
|
|
Feb 20
2024
|
John P. Saharek CEO of ImprimisRx |
SELL
Exercise of conversion of derivative security
|
Direct |
12,616
-4.81%
|
$126,160
$10.67 P/Share
|
|
Feb 20
2024
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.26%
|
$300,000
$10.67 P/Share
|
|
Feb 07
2024
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,400
+1.35%
|
$51,800
$7.71 P/Share
|
|
Feb 07
2024
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,400
+0.75%
|
$107,800
$7.71 P/Share
|
|
Nov 16
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
7,500
+0.37%
|
$60,000
$8.11 P/Share
|
|
Nov 15
2023
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.68%
|
$200,000
$8.03 P/Share
|
|
Nov 10
2023
|
John P. Saharek CEO of ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
9,778
-4.04%
|
$117,336
$12.83 P/Share
|
|
Nov 10
2023
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+7.63%
|
-
|
|
Sep 20
2023
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,983
+0.17%
|
$83,762
$14.49 P/Share
|
|
Sep 19
2023
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
14,017
+0.39%
|
$196,238
$14.65 P/Share
|
|
Aug 14
2023
|
Martin A. Makary Director |
BUY
Open market or private purchase
|
Direct |
20,000
+30.77%
|
$320,000
$16.92 P/Share
|
|
Aug 14
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
5,800
+0.29%
|
$98,600
$17.05 P/Share
|
|
Jul 18
2023
|
John P. Saharek CEO of ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
109,080
-32.93%
|
$1,963,440
$18.23 P/Share
|
|
Jul 18
2023
|
John P. Saharek CEO of ImprimisRx |
BUY
Exercise of conversion of derivative security
|
Direct |
277,200
+45.56%
|
-
|
|
Jul 18
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
299,968
-12.99%
|
$5,399,424
$18.23 P/Share
|
|
Jul 18
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
762,300
+24.82%
|
-
|
|
Jul 18
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
136,350
-20.34%
|
$2,454,300
$18.23 P/Share
|
|
Jul 18
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
346,500
+34.07%
|
-
|
|
Apr 03
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
117,633
-7.07%
|
$2,352,660
$20.97 P/Share
|
|
Apr 03
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
180,000
+9.76%
|
$1,440,000
$8.99 P/Share
|
|
Mar 31
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
34,442
-9.61%
|
$723,282
$21.16 P/Share
|
|
Mar 31
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+20.07%
|
$540,000
$6.0 P/Share
|
|
Jan 02
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
35,179
-2.31%
|
$492,506
$14.76 P/Share
|
|
Jan 02
2023
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
88,000
+5.47%
|
-
|
|
Jan 02
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
9,602
-3.45%
|
$134,428
$14.76 P/Share
|
|
Jan 02
2023
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,000
+7.64%
|
-
|
|
Dec 22
2022
|
R. Lawrence Van Horn Director |
BUY
Open market or private purchase
|
Direct |
1,860
+50.0%
|
$24,180
$13.42 P/Share
|
|
Dec 22
2022
|
Andrew R. Boll CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
2,500
+0.97%
|
$32,500
$13.54 P/Share
|
|
Dec 22
2022
|
Mark L Baum CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
25,000
+1.72%
|
$325,000
$13.39 P/Share
|
|
Dec 21
2022
|
Martin A. Makary Director |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$325,000
$13.37 P/Share
|
|
Dec 14
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
431,183
+9.4%
|
$4,311,830
$10.52 P/Share
|
|
Sep 30
2022
|
Richard L Md Lindstrom Director |
SELL
Open market or private sale
|
Indirect |
40,000
-60.51%
|
$480,000
$12.62 P/Share
|
|
Sep 28
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
11,085
+0.5%
|
$99,765
$9.77 P/Share
|
|
Apr 13
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
12,832
+1.04%
|
$76,992
$6.76 P/Share
|
|
Apr 12
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
28,557
+1.51%
|
$171,342
$6.75 P/Share
|
|
Feb 19
2022
|
John P. Saharek CEO of ImprimisRx |
SELL
Payment of exercise price or tax liability
|
Direct |
25,923
-32.4%
|
$181,461
$7.87 P/Share
|